Rezolute, Inc. (RZLT) · Nov 5, 2026 · Earnings
In line — EPS $(0.18) vs ~$0.18 consensus
Rezolute earnings were in line with expectations, but cash and investments declined ahead of the company’s pivotal upLIFT data expected in December.
Rezolute is a late-stage rare-disease biotech trying to turn ersodetug into a treatment for refractory hypoglycemia, with its congenital-HI program seeking a regulatory path after the sunRIZE trial missed its primary and key secondary endpoints, while the tumor-HI upLIFT study is the next major clinical test. The company has said upLIFT topline results are expected by mid-December 2026, and its broader plan still points toward a potential 2027 BLA.
The quarter itself was exactly where expectations were: diluted loss per share was $0.18, matching the published consensus of roughly $0.18, so the financial result does not reset the near-term operating story. The filing shows R&D and G&A costs were broadly controlled, but that is routine for a development-stage biotech without commercial revenue.
| Metric | Current period | Comparison | Market / prior |
|---|---|---|---|
| Diluted loss per share (Income Statement) | $(0.18) | $(0.18) | ~$0.18 consensus |
| R&D expense (Income Statement) | $12.8M | $13.1M | |
| Net loss (Income Statement) | $(18.5)M | $(18.2)M | |
| Cash and equivalents (Balance Sheet) | $8.2M | $10.6M | |
| Marketable debt securities (Balance Sheet) | $81.8M | $97.2M |
Liquidity moved in the wrong direction, even though the total reserve remains meaningful. Cash plus marketable securities fell from about $107.8 million at June 30 to about $90.0 million at September 30, a roughly $17.8 million quarterly decline. That makes financing and spending discipline increasingly relevant as the company approaches the upLIFT readout and potential regulatory work, although the filing does not announce a new financing or change the development plan.
The clinical story was reaffirmed, not improved. The release repeats the mid-December upLIFT timing and maintains the possibility of a 2027 BLA, but it adds no new efficacy evidence and no resolution of FDA’s review of the failed sunRIZE endpoint package. 〔0〕
Bottom line: This is an in-line earnings print, not a new clinical catalyst. The story is still riding on December’s upLIFT data, while the quarter’s falling liquidity modestly worsens the funding backdrop rather than changing the program’s direction.
upLIFT topline results, mid-December 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!